0433 GMT - Telix Pharmaceuticals' Australia-listed stock looks materially undervalued to UBS analysts given the strength of its therapeutic pipeline. They point out that the stock has been trading below what they calculate to be the combined valuation of Telix's Illuccix, Gozellix, Pixclara and Zircaix products, all of which are either approved for use in the U.S. or stand a good chance of being approved. The scientific and clinical failure that the valuation implies is highly unlikely, they write in a note to clients. With no obvious need to raise external funds and a U.S. manufacturing base, UBS keeps its buy rating and A$36.00 target price on Telix. Shares are up 7.0% at A$24.78. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 08, 2025 00:33 ET (04:33 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.